お知らせ • Apr 16
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 04/14/2026, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Jan 15
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 01/14/2026, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Oct 16
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 10/15/2025, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Oct 07
Cannabis Bioscience International Holdings, Inc Appoints Andy Trivedi to Its Board of Directors Cannabis Bioscience International Holdings, Inc. announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder value. A decorated U.S. Marine Corps veteran and seasoned financial strategist, Mr. Trivedi brings over two decades of leadership experience spanning Fortune 500 corporations, entrepreneurial ventures, and emerging growth sectors. His expertise in capital raising, financial structuring, and corporate growth strategy will directly support CBIH's plans for expansion and innovation in the rapidly evolving biomedical cannabis industry. Mr. Trivedi currently serves as Chief Financial Officer of Newable Power LLC, where he has successfully led capital development and financial planning for high-growth energy ventures. His prior leadership roles at Hewlett-Packard, GE, Air Liquide, Siemens, and FMC underscore a proven track record in building scalable business models and forging strategic partnerships across global industries. As a member of the Board, Mr. Trivedi will lead CBIH's efforts in capital strategy, investor engagement, and long-term corporate development, reinforcing the Company's ability to attract institutional partners and advance its position in medical cannabis research. Mr. Trivedi earned his MBA in Strategic Management from the UHV and a BBA in Risk Management and Finance from the UHD. In addition to his corporate achievements, he has been an active supporter of veteran initiatives and small business development programs, underscoring his commitment to community and sustainable growth. By integrating proven financial leadership into its governance structure, CBIH is positioning itself to seize upcoming opportunities in the medical cannabis sector and deliver sustainable value for shareholders. お知らせ • Sep 03
Cannabis Bioscience International Holdings, Inc. announced delayed annual 10-K filing On 09/02/2025, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Apr 15
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 04/14/2025, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Jan 14
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 01/13/2025, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Nov 26
Cannabis Bioscience International Holdings, Inc. Unveils the Future of Wellness with Revolutionary Anti-Aging Chip Cannabis Bioscience International Holdings, Inc. continues to set a standard in innovation with unparalleled momentum in intellectual property development. The company proudly stands with a remarkable portfolio of 13 unconventional patents. In addition, its Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuvenescence Chip, a pioneering advancement in anti-aging medicine. This cutting-edge device redefines wellness by delivering a controlled release of active ingredients combining phytocannabinoids and gestrinone, offering a long-term solution for aesthetics, hormonal health, and sexual well-being. For sexual health, it enhances libido, improves sexual response, and elevates mood and overall quality of life. Additionally, its anti-inflammatory properties provide protection against estrogen-dominance-related conditions, such as endometriosis. Beyond these physical benefits, the treatment supports emotional well-being, instilling confidence and vitality in women, empowering them to feel more in control of their personal lives, and fostering deeper, more fulfilling relationships, enhancing both individual well-being and interpersonal connection. CBIH remains committed to advancing the patent for this revolutionary anti-ageing technology and continues to push the boundaries of cannabinoid therapy in cosmetics and pharmaceuticals. By leveraging next-generation technology, CBIH is setting new standards for therapeutic advancements and is poised to lead the charge in unlocking the full potential of cannabinoids in both medicine and beauty. お知らせ • Oct 12
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 10/11/2024, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Aug 27
Cannabis Bioscience International Holdings, Inc. announced delayed annual 10-K filing On 08/26/2024, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Jun 27
Cannabis Bioscience International Holdings, Inc. Appoints John Jones as Treasurer and Director Cannabis Bioscience International Holdings introduced the strategies formulated by its freshly appointed Treasurer and Director, Mr. John Jones, who has facilitated a series of insightful discussions and established official communications between CBIH and a pioneering company in innovative product and packaging solutions for globally recognized brands. As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's product distributor, utilizing its expertise across various sectors such as retail, industrial packaging, manufacturing, production management, product marketing, fulfillment services, design services, and inventory management. お知らせ • Apr 16
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 04/15/2024, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Feb 28
Cannabis Bioscience International Holdings Elects Brian Cuban to its Advisory Board Member Cannabis Bioscience International Holdings is excited to announced that Brian Cuban has been elected by firm as an Advisory Board Member. Mr. Cuban will bring decades of experience in legal and corporate leadership, and a long track record of coaching diverse professionals around the world. Brian Cuban, the younger brother of the former principal owner of the Dallas Mavericks, Mark Cuban, is an attorney, author, and mental health awareness and recovery advocate. He is a graduate of Penn State University and The University of Pittsburgh School of Law. Brian has been in long-term recovery from alcohol, cocaine, and bulimia since April of 2007. お知らせ • Jan 14
Cannabis Bioscience International Holdings, Inc. announced delayed 10-Q filing On 01/12/2024, Cannabis Bioscience International Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Oct 29
China Infrastructure Construction Corp. (OTCPK:CHNC) acquired Pharmacology University, Inc. China Infrastructure Construction Corp. (OTCPK:CHNC) acquired Pharmacology University, Inc. on October 28, 2020.
China Infrastructure Construction Corp. (OTCPK:CHNC) completed the acquisition of Pharmacology University, Inc. on October 28, 2020.